<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828449</url>
  </required_header>
  <id_info>
    <org_study_id>2014-12</org_study_id>
    <nct_id>NCT02828449</nct_id>
  </id_info>
  <brief_title>Assesment of the Implementation of a Therapeutic Educational Intervention Affecting Adherence to Oral Chemotherapy</brief_title>
  <acronym>CHIMIO ORALE</acronym>
  <official_title>Assessment of the Implementation of a Therapeutic Educational Intervention Affecting Adherence to Oral Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutic education is an effective way to support the prescription of oral chemotherapy in
      oncology. It aims to increase adherence to treatment, to better control the side effects and
      reduce unplanned readmissions. The three major oncology institutions in the Rhône-Alpes
      region (Hospices Civils de Lyon, the Centre Léon Bérard Cancer Institute and Lucien Neuwirth)
      decided to collaborate on a project to implement an adapted Therapeutic Education Program
      context of each of these institutions.

      The objective of this study is to evaluate the implementation of the intervention in the 3
      participating centers, over 1 year:

        1. Assess the achievement of the target population

        2. Evaluate the adaptation of intervention in context

        3. Evaluate the effectiveness of the intervention (impact): effectiveness in real life,
           identification of interactions with the environment linked to the center, identification
           of unintended effects of the intervention.

        4. Assessing the sustainability of the intervention
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of affected population</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of acquisition of knowledge</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire composed of numerous questions dealing with patient's knowledge about his/her disease, treatment and treatment's side effects . Answers are quoted in Yes/No and a global scoring is made with all answers. Final measure is a percentage of good answers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anxiety and Depression</measure>
    <time_frame>3 months</time_frame>
    <description>measured with the Hospital Anxiety Depression Scale (Zigmond &amp; Snaith, 1983 ), wich gives separated results about the level of anxiety and of depression according to the level of scoring to a set of 14 questions. Questions are rated from 0-3, and the anxiety and depression subscale scores range from 0-21. The cutoff for each subscale is eight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Questionnaire</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Morisky Measurement Adherence Scale</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Neoplasm</condition>
  <arm_group>
    <arm_group_label>therapeutic education program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapeutic education program which aims is to improve the adherence to the treatment and management of adverse effects of this treatment in patients taking an oral chemotherapy for active cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>therapeutic education program</intervention_name>
    <arm_group_label>therapeutic education program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient care in medical oncology services of the Cancer Institute of Lucien Neuwirth,
             the Lyon-Sud hospital and the Centre Léon Bérard:

          -  Age over 18 years

          -  Introducing an active cancer (local extension, locoregional or metastatic)

          -  Oral chemotherapy as monotherapy or in combination with other treatments, initiated or
             in progress

        Exclusion Criteria:

          -  Refusal to participate, protected adult patient under guardianship.

          -  Patient disability to understand the course of the study, the Therapeutic education
             program, or failure to follow the educational sessions.

          -  Patient with documented history of cognitive or psychiatric disorders.

          -  Patient on adjuvant therapy or hormone therapy for prostate cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aurélie BOURMAUD, MD</last_name>
    <phone>04 77 91 74 77</phone>
    <email>aurelie.bourmaud@icloire.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David PEROL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Falandry, PhDMD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Vassal, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

